Kite Pharma (NASDAQ: KITE) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Profitability

This table compares Kite Pharma and Axsome Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kite Pharma -1,092.54% -59.15% -48.12%
Axsome Therapeutics N/A -116.34% -74.68%

Earnings & Valuation

This table compares Kite Pharma and Axsome Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Kite Pharma N/A N/A N/A ($6.87) N/A
Axsome Therapeutics N/A N/A -$27.20 ($1.47) N/A

Volatility & Risk

Kite Pharma has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Kite Pharma and Axsome Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kite Pharma 0 10 7 0 2.41
Axsome Therapeutics 0 0 4 0 3.00

Kite Pharma currently has a consensus target price of $93.20, suggesting a potential upside of Infinity. Axsome Therapeutics has a consensus target price of $19.50, suggesting a potential upside of Infinity.

Institutional and Insider Ownership

87.7% of Kite Pharma shares are held by institutional investors. Comparatively, 27.1% of Axsome Therapeutics shares are held by institutional investors. 14.0% of Kite Pharma shares are held by company insiders. Comparatively, 35.2% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Kite Pharma beats Axsome Therapeutics on 5 of the 9 factors compared between the two stocks.

About Kite Pharma

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.